









Markets
/
Stocks
/
nasdaq-ghrs
/

GH Research PLC

GHRS

13.530USD

-0.790-5.52%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

812.33MMarket Cap

LossP/E TTM



GH Research PLC

13.530

-0.790-5.52%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of GH Research PLC

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GH Research PLC's Score

Industry at a Glance

Industry Ranking

206 / 501

Overall Ranking

362 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

31.125

Target Price

+117.35%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

GH Research PLC Highlights

StrengthsRisks

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -19.43, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 43.68M shares, decreasing 2.83% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

GH Research PLC's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.97, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -19.43, which is -51.89% below the recent high of -9.35 and -36.22% above the recent low of -26.47.

Score

Industry at a Glance

Previous score

6.97

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 206/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for GH Research PLC is 31.00, with a high of 40.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

31.125

Target Price

+117.35%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

GH Research PLC

GHRS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 8.93, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 15.39 and the support level at 12.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.73

Change

0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.031

Buy

RSI(14)

50.051

Neutral

STOCH(KDJ)(9,3,3)

53.741

Neutral

ATR(14)

1.072

Low Volatility

CCI(14)

38.725

Neutral

Williams %R

54.800

Neutral

TRIX(12,20)

0.082

Sell

StochRSI(14)

58.290

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

13.632

Sell

MA10

13.522

Buy

MA20

13.467

Buy

MA50

13.457

Buy

MA100

13.653

Sell

MA200

12.410

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 70.41%, representing a quarter-over-quarter decrease of 31.47%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Schonharting (Florian)

14.82M

BVF Partners L.P.

8.83M

RA Capital Management, LP

7.68M

+10.54%

Lynx1 Capital Advisors LLC

6.75M

+4.70%

RTW Investments L.P.

5.54M

+0.74%

Fidelity Management & Research Company LLC

5.09M

+19.83%

Terwey (Theis)

4.69M

-24.16%

Cormorant Asset Management, LP

2.01M

Deep Track Capital LP

2.00M

TD Securities, Inc.

1.97M

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.